Neuphoria Therapeutics Inc.

NEUP

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001191070

None

No letter

4 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $28.7M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	dilution, late filer, thin data not computable: distress, fortress balance sheet
Inputs computable	4 of 14
Graded from	filings received through Sep 18, 2026 39 days before the rescan; latest periodic filing 10-K received Sep 18, 2026
Last close	$3.37 2026-10-26; market equity $18.2M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Sep 18, 2026

Neuphoria Therapeutics Inc. is a Delaware corporation and a clinical-stage biotechnology company. Following the results of our Phase 3 AFFIRM-1 trial and the restructuring actions taken during fiscal 2026, our activities are focused on completing the proposed merger with Scancell Holdings plc ("Scancell"), preserving cash, maintaining our public-company and contractual obligations, and managing our intellectual property and economic interests in partnered programs. We are currently conducting limited active internal research and development activities focused on our alpha7 nicotinic acetylcholine receptor negative allosteric modulator portfolio.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 66.9						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing						
Accruals ratio	(3.8%)	(6.6%)		66.9	805	2026-06-30
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 35.6						
Twelve-month failure probability	not computable	0.07%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	(14.70)	(0.33)		69.6	751	2026-06-30
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	27.85x	2.94x		1.7	832	2026-06-30
Growth and financing, sleeve percentile 85.8						
Revenue growth, three-year compound	not computable	10.1%				
four annual observations are required; found 2						
Free cash flow growth, three-year compound	not computable	10.9%				
four consecutive annual FCF observations are required; found 0						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	not computable	2.1%				
four annual observations are required; found 3						
Net share issuance, one year	129.5%	2.5%		85.8	634	2026-09-17

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 129.5%
Late filer	found 1 NT 10-K/Q filings in the last eight quarters
Thin data	4 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-26 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(68.1%)	7.7%	7
Distance from 52-week high	(45.8%)	(31.2%)	32
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	1.34	0.28	91
Sales to price	0.06	0.30	18
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(1.36)	(0.14)	7

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2026-06-30	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$19.9M
Operating cash flow, four quarters	-$12.4M
Months of runway	19.3
Days since last periodic filing	39 (10-K received Sep 18, 2026)
Median daily dollar volume, 63 sessions	$79,857

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$13.5M	2026-06-30	2026-09-18	10-K	26-395536
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$12.4M	2026-06-30	2026-09-18	10-K	26-395536
3	assets	us-gaap:Assets	$28.7M	2026-06-30	2026-09-18	10-K	26-395536
4	assets	us-gaap:Assets	$28.6M	2025-06-30	2026-09-18	10-K	26-395536
5	current assets	us-gaap:AssetsCurrent	$21.1M	2026-06-30	2026-09-18	10-K	26-395536
6	current liabilities	us-gaap:LiabilitiesCurrent	$756,581	2026-06-30	2026-09-18	10-K	26-395536
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$191.8M	2026-06-30	2026-09-18	10-K	26-395536
8	operating income	us-gaap:OperatingIncomeLoss	-$16.5M	2026-06-30	2026-09-18	10-K	26-395536
9	book equity	us-gaap:StockholdersEquity	$24.6M	2026-06-30	2026-09-18	10-K	26-395536
10	liabilities	us-gaap:Liabilities	$4.1M	2026-06-30	2026-09-18	10-K	26-395536
11	revenue	us-gaap:Revenues	$1.2M	2026-06-30	2026-09-18	10-K	26-395536
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$15.6M	2025-06-30	2025-09-29	10-K	25-223338
13	assets	us-gaap:Assets	$27.6M	2024-06-30	2025-09-29	10-K	25-223338
14	shares outstanding	dei:EntityCommonStockSharesOutstanding	5,411,334	2026-09-17	2026-09-18	10-K	26-395536
15	shares outstanding	dei:EntityCommonStockSharesOutstanding	2,357,613	2025-09-29	2025-09-29	10-K	25-223338

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.